| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -30,476,921 | -14,732,305 |
| Loss on foreign exchange | -16,953 | -1,712 |
| Amortization of loan costs | 52,373 | 52,373 |
| Depreciation | 2,063 | 34,278 |
| Reduction in carrying amount of right-of-use asset | 49,553 | - |
| Loss on debt conversion with related party | -6,134,120 | -6,134,120 |
| Acquisition of license for research and development | 12,030,667 | - |
| Deferred tax expense | 189,255 | 190,691 |
| Share-based compensation expense | 197,782 | 149,501 |
| Decrease in prepaid expenses and other current assets | -168,873 | -396,528 |
| (decrease) increase in accounts payable | -651,572 | -738,306 |
| Increase in accrued expenses and other liabilities | 305,390 | -197,264 |
| Net cash used in operating activities | -11,981,464 | -8,708,672 |
| Proceeds from registered direct offering of common stock, net of offering costs | 4,252,245 | 4,252,245 |
| Proceeds from loan with related party | 3,000,000 | 3,000,000 |
| Net cash provided by financing activities | 7,252,245 | 7,252,245 |
| Net decrease in cash | -4,729,219 | -1,456,427 |
| Cash and cash equivalents at beginning of period | 14,847,949 | - |
| Effect of exchange rate changes on cash | 7,980 | - |
| Cash and cash equivalents at end of period | 10,126,710 | - |
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)